Overweight Clinical Trials in San Antonio, Texas
17 recruitingSan Antonio, Texas
Showing 1–17 of 17 trials
Recruiting
Phase 2
Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
Overweight or Obesity
Regeneron Pharmaceuticals120 enrolled3 locationsNCT07431086
Recruiting
Phase 2
A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight
Overweight or Obesity and Elevated Liver Fat
Amgen180 enrolled15 locationsNCT07441252
Recruiting
Phase 3
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
ObesityOverweightAtherosclerotic Cardiovascular Disease
Amgen12,800 enrolled759 locationsNCT07037433
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,980 enrolled173 locationsNCT07321886
Recruiting
Phase 2
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
ObesityOverweight
Eli Lilly and Company1,217 enrolled53 locationsNCT06143956
Recruiting
Phase 1
A Study of LY4064912 in Healthy Participants and With Overweight or Obesity
HealthyOverweight or Obesity
Eli Lilly and Company144 enrolled3 locationsNCT07152002
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
ObesityOverweightSleep Apnea, Obstructive
Eli Lilly and Company800 enrolled123 locationsNCT07369011
Recruiting
Phase 4
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
PsoriasisOverweight or Obesity
Eli Lilly and Company200 enrolled43 locationsNCT06857942
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
ObesityOverweight
Eli Lilly and Company900 enrolled178 locationsNCT07392190
Recruiting
Phase 1
A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes
ObesityHealthyOverweight+1 more
Eli Lilly and Company216 enrolled6 locationsNCT06945419
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled159 locationsNCT07282600
Recruiting
Phase 3
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Crohn's DiseaseObesity or Overweight
Eli Lilly and Company290 enrolled187 locationsNCT06937099
Recruiting
Phase 3
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
OsteoarthritisOverweight or Obesity
Eli Lilly and Company900 enrolled154 locationsNCT07353931
Recruiting
Phase 3
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
Ulcerative ColitisObesity or Overweight
Eli Lilly and Company350 enrolled191 locationsNCT06937086
Recruiting
Phase 3
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
ObesityOverweight
Novo Nordisk A/S460 enrolled119 locationsNCT07253285
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
ObesityOverweight
Eli Lilly and Company250 enrolled31 locationsNCT07232719
Recruiting
Phase 1
A Study on How NNC0174-1213 Works in People With Overweight or Obesity.
ObesityOverweight
Novo Nordisk A/S177 enrolled2 locationsNCT06719011